Source link : https://www.newshealth.biz/health-news/fda-oks-iqirvo-first-in-class-ppar-treatment-for-pbc/
The US Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo (elafibranor; Ipsen) for treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who do not respond adequately to UDCA or as monotherapy in patients unable to tolerate UDCA. PBC is a rare, chronic cholestatic liver disease that […]
Author : News Health
Publish date : 2024-06-11 16:13:23
Copyright for syndicated content belongs to the linked Source.